RU2017102769A3 - - Google Patents

Info

Publication number: RU2017102769A3
Authority: RU; Russia

Application number

RU2017102769A

Other versions

RU2017102769A (ru

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-07-29

Filing date

2015-07-29

Publication date

2018-08-28

2015-07-29 Application filed filed Critical

2018-08-28 Publication of RU2017102769A3 publication Critical patent/RU2017102769A3/ru

2018-08-28 Publication of RU2017102769A publication Critical patent/RU2017102769A/ru

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4203—Receptors for growth factors
- A61K40/4204—Epidermal growth factor receptors [EGFR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/47—Brain; Nervous system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Epidemiology (AREA)
Cell Biology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Developmental Biology & Embryology (AREA)
Virology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

RU2017102769A 2014-07-29 2015-07-29 EGFRvIII СПЕЦИФИЧЕСКИЕ ХИМЕРНЫЕ АНТИГЕННЫЕ РЕЦЕПТОРЫ ДЛЯ ИММУНОТЕРАПИИ РАКА RU2017102769A (ru)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DKPA201470466		2014-07-29
DKPA201470466		2014-07-29
PCT/EP2015/067439 WO2016016341A1 (en)	2014-07-29	2015-07-29	EGFRvIII SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR CANCER IMMUNOTHERAPY

Publications (2)

Publication Number	Publication Date
RU2017102769A3 true RU2017102769A3 (ru)	2018-08-28
RU2017102769A RU2017102769A (ru)	2018-08-28

Family

ID=51300485

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RU2017102769A RU2017102769A (ru)	2014-07-29	2015-07-29	EGFRvIII СПЕЦИФИЧЕСКИЕ ХИМЕРНЫЕ АНТИГЕННЫЕ РЕЦЕПТОРЫ ДЛЯ ИММУНОТЕРАПИИ РАКА

Country Status (12)

Country	Link
US (1)	US20170275366A1 (ru)
EP (1)	EP3174556A1 (ru)
JP (1)	JP2017522884A (ru)
KR (2)	KR20180125632A (ru)
CN (1)	CN107074973A (ru)
AU (1)	AU2015295346A1 (ru)
BR (1)	BR112017001818A2 (ru)
CA (1)	CA2956307A1 (ru)
IL (1)	IL250339A0 (ru)
MX (1)	MX2017001229A (ru)
RU (1)	RU2017102769A (ru)
WO (1)	WO2016016341A1 (ru)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI755547B (zh)	2016-01-21	2022-02-21	美商輝瑞股份有限公司	靶向表皮生長因子受體變異體iii之嵌合型抗原受體
CN109219618B (zh)	2016-01-21	2022-08-09	辉瑞大药厂	针对表皮生长因子受体变体iii和cd3的单特异性和双特异性抗体及其用途
WO2018014039A1 (en) *	2016-07-15	2018-01-18	Poseida Therapeutics, Inc.	Chimeric antigen receptors (cars) specific for muc1 and methods for their use
MX2019003768A (es)	2016-10-03	2019-06-24	Juno Therapeutics Inc	Moleculas de enlace especificas de hpv.
DK3523326T3 (da) *	2016-10-04	2020-08-03	Prec Biosciences Inc	Samstimulerende domæner til anvendelse i genetisk modificerede celler
CN110520530A (zh) *	2016-10-18	2019-11-29	明尼苏达大学董事会	肿瘤浸润性淋巴细胞和治疗方法
CN108276493B (zh) *	2016-12-30	2023-11-14	南京传奇生物科技有限公司	一种嵌合抗原受体及其应用
EP3568466A4 (en)	2017-01-10	2020-07-15	The General Hospital Corporation	TARGETED T CELLS WITH CYTOTOXICITY TO IMMUNOSUPPRESSIVE CELLS
US12378297B2 (en) *	2017-04-14	2025-08-05	The General Hospital Corporation	Chimeric antigen receptor T cells targeting the tumor microenvironment
KR102302714B1 (ko) *	2017-04-26	2021-09-17	주식회사 파이안바이오테크놀로지	신호전달 막단백질의 경막 부위를 이용한 목적단백질의 인간세포 막 표면 발현 방법
JP2020537515A (ja)	2017-10-03	2020-12-24	ジュノーセラピューティクスインコーポレイテッド	Ｈｐｖ特異的結合分子
CN109694854B (zh) *	2017-10-20	2023-11-21	亘喜生物科技（上海）有限公司	通用型嵌合抗原受体t细胞制备技术
CN109750035B (zh) *	2017-11-02	2020-06-05	上海邦耀生物科技有限公司	靶向并引导Cas9蛋白高效切割TCR及B2M基因座的sgRNA
WO2019114751A1 (zh) *	2017-12-12	2019-06-20	科济生物医药（上海）有限公司	免疫效应细胞和辐射联用治疗肿瘤
MA52207A (fr)	2018-04-05	2021-02-17	Editas Medicine Inc	Lymphocytes t exprimant un récepteur recombinant, polynucléotides et procédés associés
EP3773908A1 (en)	2018-04-05	2021-02-17	Juno Therapeutics, Inc.	T cell receptors and engineered cells expressing same
CA3094468A1 (en)	2018-04-05	2019-10-10	Juno Therapeutics, Inc.	Methods of producing cells expressing a recombinant receptor and related compositions
AU2019250692A1 (en) *	2018-04-13	2020-11-05	Sangamo Therapeutics France	Chimeric antigen receptor specific for Interleukin-23 receptor
MX2020012028A (es)	2018-05-11	2021-03-29	Crispr Therapeutics Ag	Metodos y composiciones para tratar el cancer.
WO2019241315A1 (en)	2018-06-12	2019-12-19	Obsidian Therapeutics, Inc.	Pde5 derived regulatory constructs and methods of use in immunotherapy
CN114957475B (zh) *	2018-09-26	2023-06-20	福州拓新天成生物科技有限公司	抗b7-h3的单克隆抗体及其在细胞治疗中的应用
CN112770697B (zh)	2018-09-26	2024-05-14	W.L.戈尔及同仁股份有限公司	具有可控细胞床厚度的细胞封装设备
US20210386788A1 (en)	2018-10-24	2021-12-16	Obsidian Therapeutics, Inc.	Er tunable protein regulation
CN109485731A (zh) *	2018-11-02	2019-03-19	广东克瑞斯普生物科技有限公司	一种靶向EGFRvIII的嵌合抗原受体
JP7455127B2 (ja) *	2018-12-20	2024-03-25	オスロユニヴェルジテットサイケフスホーエフ	キメラ抗原受容体（ｃａｒ）および医薬におけるその使用
CR20210330A (es) *	2018-12-21	2021-07-20	Hoffmann La Roche	ANTICUERPOS QUE SE UNEN A CD3 (Divisional 2021-0325)
EP3769816A1 (en) *	2019-07-25	2021-01-27	Ospedale Pediatrico Bambino Gesù	Car-cd123 vector and uses thereof
WO2021046451A1 (en)	2019-09-06	2021-03-11	Obsidian Therapeutics, Inc.	Compositions and methods for dhfr tunable protein regulation
JP2023531531A (ja)	2020-06-26	2023-07-24	ジュノセラピューティクスゲーエムベーハー	組換え受容体を条件付きで発現する操作されたｔ細胞、関連ポリヌクレオチド、および方法
AR124414A1 (es)	2020-12-18	2023-03-22	Century Therapeutics Inc	Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
KR20230122618A (ko)	2020-12-21	2023-08-22	알로젠 테라퓨틱스 인코포레이티드	프로테아제 활성화 cd45-게이트 car
CA3204417A1 (en)	2021-01-29	2022-08-04	Allogene Therapeutics, Inc.	Knockdown or knockout of one or more of tap2, nlrc5, ?2m, trac, rfx5, rfxap and rfxank to mitigate t cell recognition of allogeneic cell products
CN114907486A (zh) *	2021-02-09	2022-08-16	上海怀越生物科技有限公司	Egfr靶向性嵌合抗原受体及其制备方法及应用
CN114917329B (zh) *	2021-02-11	2023-07-21	兰州大学第二医院	抗cd87抗体与抗pd1抗体联合治疗胃癌
CN117693508A (zh)	2021-03-03	2024-03-12	朱诺治疗学股份有限公司	T细胞疗法和dgk抑制剂的组合
AU2022267410A1 (en) *	2021-04-26	2023-11-09	Myrio Therapeutics Pty Ltd	EGFRvIII BINDING PROTEINS
US20250121002A1 (en) *	2021-07-16	2025-04-17	Noile-Immune Biotech Inc.	ANTI-EGFRviii ANTIBODY, POLYPEPTIDE, CELL CAPABLE OF EXPRESSING SAID POLYPEPTIDE, PHARMACEUTICAL COMPOSITION COMPRISING SAID CELL, METHOD FOR PRODUCING SAID CELL, AND POLYNUCLEOTIDE OR VECTOR COMPRISING NUCLEOTIDE SEQUENCE ENCODING SAID POLYPEPTIDE
WO2023081900A1 (en)	2021-11-08	2023-05-11	Juno Therapeutics, Inc.	Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
WO2024010119A1 (ko) *	2022-07-07	2024-01-11	주식회사 유틸렉스	돌연변이 egfr 및 epha2를 동시 타겟하는 키메라 항원 수용체
CA3261440A1 (en)	2022-07-29	2024-02-01	Allogene Therapeutics, Inc.	MODIFIED CELLS WITH REDUCED GENE EXPRESSION TO MITIGATE RECOGNITION BY IMMUNE CELLS
AU2023325086A1 (en) *	2022-08-16	2025-01-09	Allogene Therapeutics Inc.	In vitro method for inhibiting hhv-6 infection
EP4583876A1 (en)	2022-09-08	2025-07-16	Juno Therapeutics, Inc.	Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
WO2024100604A1 (en)	2022-11-09	2024-05-16	Juno Therapeutics Gmbh	Methods for manufacturing engineered immune cells
JP2026504491A (ja)	2023-02-03	2026-02-05	ツェー３エス２ゲーエムベーハー	操作された免疫細胞の非ウイルス的製造のための方法
AU2024372734A1 (en)	2023-10-30	2026-04-16	Allogene Therapeutics, Inc.	Engineered cells
WO2026025092A1 (en)	2024-07-26	2026-01-29	Juno Therapeutics, Inc.	Synthetic promoters for t cell expression

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU687010B2 (en) *	1992-07-17	1998-02-19	Dana-Farber Cancer Institute	Method of intracellular binding of target molecules
US20080045437A1 (en) *	2006-03-10	2008-02-21	Barbara Pfeifer	Soap bar with hidden indicia
WO2008045437A2 (en) *	2006-10-09	2008-04-17	The General Hospital Corporation	Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
US20120079000A1 (en) *	2010-09-27	2012-03-29	Motorola-Mobility, Inc.	Selectively receiving media content
PH12013501201A1 (en) *	2010-12-09	2013-07-29	Univ Pennsylvania	Use of chimeric antigen receptor-modified t cells to treat cancer
KR20140004174A (ko) *	2011-01-18	2014-01-10	더 트러스티스 오브 더 유니버시티 오브 펜실바니아	암 치료를 위한 조성물 및 방법
CA2832540C (en) *	2011-04-08	2020-09-15	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
MX367730B (es) *	2012-09-04	2019-09-04	Cellectis	Receptor de antigeno quimerico multi-cadena y usos del mismo.
RU2658485C2 (ru) *	2012-10-24	2018-06-21	Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез	Химерные антигенные рецепторы м971
JP6647868B2 (ja) *	2013-02-20	2020-02-14	ノバルティスアーゲー	ヒト化抗ＥＧＦＲｖＩＩＩキメラ抗原受容体を用いたがんの処置
EP3087101B1 (en) *	2013-12-20	2024-06-05	Novartis AG	Regulatable chimeric antigen receptor

2015
- 2015-07-29 WO PCT/EP2015/067439 patent/WO2016016341A1/en not_active Ceased
- 2015-07-29 RU RU2017102769A patent/RU2017102769A/ru not_active Application Discontinuation
- 2015-07-29 EP EP15744213.8A patent/EP3174556A1/en not_active Withdrawn
- 2015-07-29 BR BR112017001818A patent/BR112017001818A2/pt not_active Application Discontinuation
- 2015-07-29 KR KR1020187033242A patent/KR20180125632A/ko not_active Withdrawn
- 2015-07-29 CN CN201580050653.3A patent/CN107074973A/zh active Pending
- 2015-07-29 CA CA2956307A patent/CA2956307A1/en not_active Abandoned
- 2015-07-29 MX MX2017001229A patent/MX2017001229A/es unknown
- 2015-07-29 JP JP2017504153A patent/JP2017522884A/ja active Pending
- 2015-07-29 US US15/526,649 patent/US20170275366A1/en not_active Abandoned
- 2015-07-29 AU AU2015295346A patent/AU2015295346A1/en not_active Abandoned
- 2015-07-29 KR KR1020177005490A patent/KR20170036087A/ko not_active Ceased
2017
- 2017-01-29 IL IL250339A patent/IL250339A0/en unknown

Also Published As

Publication number	Publication date
KR20170036087A (ko)	2017-03-31
AU2015295346A1 (en)	2017-02-16
MX2017001229A (es)	2017-05-01
WO2016016341A1 (en)	2016-02-04
RU2017102769A (ru)	2018-08-28
IL250339A0 (en)	2017-03-30
EP3174556A1 (en)	2017-06-07
KR20180125632A (ko)	2018-11-23
JP2017522884A (ja)	2017-08-17
BR112017001818A2 (pt)	2017-11-21
US20170275366A1 (en)	2017-09-28
CA2956307A1 (en)	2016-02-04
CN107074973A (zh)	2017-08-18

Legal Events

Date	Code	Title	Description
2019-07-20	HZ9A	Changing address for correspondence with an applicant
2020-10-10	FA92	Acknowledgement of application withdrawn (lack of supplementary materials submitted)	Effective date: 20200925

Publication	Publication Date	Title
BR112016018895A2 (ru)	2017-08-15
BR112016016900A2 (ru)	2017-08-08
BR112016017696A2 (ru)	2017-08-08
BR112016015376A2 (ru)	2017-08-08
BR112016017131A2 (ru)	2017-10-03
BR112016015605A2 (ru)	2017-08-08
BR112016016546A2 (ru)	2017-08-08
BR112016018278A2 (ru)	2017-08-08
BR112016016741A2 (ru)	2017-08-08
BR112016015845A2 (ru)	2017-08-08
BR112016017226A2 (ru)	2017-08-08
BR112016013819A2 (ru)	2017-08-08
BR112016015386A2 (ru)	2017-08-08
BR112016015385A2 (ru)	2017-08-08
BR112016016106A2 (ru)	2017-08-08
BR112016018800A2 (ru)	2017-08-08
BR112016017713A2 (ru)	2017-08-08
BR112016012729A2 (ru)	2017-08-08
BR112016017660A2 (ru)	2017-08-08
BR112016017469A2 (ru)	2017-08-08
BR112016018632A2 (ru)	2017-08-08
BR112016017502A2 (ru)	2017-08-08
BR112016018401A2 (ru)	2017-08-08
BR112016017093A2 (ru)	2017-08-08
BR112016016078A2 (ru)	2017-08-08